Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 6/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | HPGD | P15428 | 3/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3398723 | 1.00 | ADORA2A (0.33) | ADORA2AADORA1KDM4EALDH1A1HPGD | |
| SCHEMBL316334 | 0.85 | PTPN2 (0.35) | ADORA2AADORA1KDM4EALDH1A1HPGD | |
| SCHEMBL316333 | 0.85 | PTPN2 (0.35) | ADORA2AADORA1KDM4EALDH1A1HPGD | |
| SCHEMBL315279 | 0.83 | JAK2 (0.35) | KDM4EALDH1A1HPGDMAPTLMNA | |
| SCHEMBL316757 | 0.83 | KDM4E (0.32) | KDM4EALDH1A1HPGDMAPTLMNA | |
| SCHEMBL316756 | 0.83 | KDM4E (0.32) | KDM4EALDH1A1HPGDMAPTLMNA | |
| SCHEMBL2142538 | 0.83 | KDM4E (0.34) | KDM4EALDH1A1HPGDMAPTLMNA | |
| SCHEMBL2142546 | 0.83 | KDM4E (0.34) | KDM4EALDH1A1HPGDMAPTLMNA | |
| SCHEMBL1973110 | 0.82 | GRIN1 (0.36) | — | |
| SCHEMBL1973109 | 0.82 | GRIN1 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093394-B2 | Derivatives of 5-thioxylopyranose and use of same for treatment | LABORATOIRES FOURNIER S.A. (FR) | 2012-01-10 | — | — | US | disclosed |
| EP-2066683-B1 | DERIVATIVES OF 5-THIOXYLOPYRANOSE AND USE OF SAME FOR TREATMENT | FOURNIER LAB SA (FR) | 2010-11-03 | — | — | EP | disclosed |
| US-20090182013-A1 | Derivatives of 5-Thioxylopyranose and Use of Same for Treatment | LABORATOIRES FOURNIER S.A. (FR) | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090182013-A1 | Derivatives of 5-Thioxylopyranose and Use of Same for Treatment | TPMT, PNPO, PPOX | ADORA2A 1894/4885ADORA1 1940/4885KDM4E 1220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.